ABL1 and acute myeloid leukemia: Our studies now demonstrate for the first time that Egr1 behaves as a tumor suppressor in a mouse model of BCR-ABL driven leukemia, and provides the impetus to study the effect of altered Egr1 in Acute Myelogenous Leukemia (AML) where the overall five year survival rate remains low.